Skip to main content
Erschienen in: Endocrine 3/2009

01.12.2009 | Original Article

Stimulation of 11β-HSD1 expression by IL-1β via a C/EBP binding site in human fetal lung fibroblasts

verfasst von: Zhen Yang, Xiaoou Zhu, Chunming Guo, Kang Sun

Erschienen in: Endocrine | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Proinflammatory cytokines, just like glucocorticoids (GCs), have been reported to upregulate 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) expression in many cell types. This concerted regulation of 11β-HSD1 by interleukin-1β (IL-1β) and GCs is in marked contrast to their antagonistic effects on inflammation. Further, the molecular mechanisms underlying the induction of 11β-HSD1 by IL-1β are not very well understood. In this study, we demonstrated that IL-1β dramatically stimulated 11β-HSD1 expression and enzyme activity as well as promoter activity including the −64 bp fragment upstream to the transcription start site in human fetal lung fibroblasts (HFL-1). Nucleotide mutations of the proximal CCAAT box within this region abolished the induction of 11β-HSD1 promoter activity by IL-1β. Western blotting analysis demonstrated that IL-1β induced the expression of C/EBPβ dramatically while C/EBPα was barely detectable in HFL-1 cells. Global inhibition of CCAAT/enhancer-binding proteins (C/EBPs) with transfection of C/EBP-specific dominant-negative expression plasmid (CMV500-A-C/EBP) significantly attenuated the induction of 11β-HSD1 by IL-1β, whereas over-expression of C/EBPβ enhanced the expression of 11β-HSD1. Chromatin immunoprecipitation assay revealed the recruitment of C/EBPβ to the promoter region containing the C/EBP binding site. In conclusion, IL-1β induces the expression of 11β-HSD1 mRNA in the fetal lung tissue through mechanisms that involve C/EBPβ binding to the promoter. This impact of IL-1β on the expression of 11β-HSD1 in human fetal lung cells may explain the alternate mechanism for the lung maturation that appears to occur when there is a risk of premature delivery of the fetus due to the presence of infection.
Literatur
1.
2.
Zurück zum Zitat K.L. Watterberg, L.M. Demers, S.M. Scott, S. Murphy, Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 97, 210–215 (1996)PubMed K.L. Watterberg, L.M. Demers, S.M. Scott, S. Murphy, Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 97, 210–215 (1996)PubMed
3.
Zurück zum Zitat R. Hayashi, H. Wada, K. Ito, I.M. Adcock, Effects of glucocorticoids on gene transcription. Eur. J. Pharmacol. 500, 51–62 (2004)CrossRefPubMed R. Hayashi, H. Wada, K. Ito, I.M. Adcock, Effects of glucocorticoids on gene transcription. Eur. J. Pharmacol. 500, 51–62 (2004)CrossRefPubMed
4.
Zurück zum Zitat J.R. Seckl, 11 Beta-hydroxysteroid dehydrogenase isoforms and their implications for blood-pressure regulation. Eur. J. Clin. Invest. 23, 589–601 (1993)CrossRefPubMed J.R. Seckl, 11 Beta-hydroxysteroid dehydrogenase isoforms and their implications for blood-pressure regulation. Eur. J. Clin. Invest. 23, 589–601 (1993)CrossRefPubMed
5.
Zurück zum Zitat A.L. Albiston, V.R. Obeyesekere, R.E. Smith, Z.S. Krozowski, Cloning and tissue distribution of the human 11-beta-hydroxysteroid dehydrogenase type-2 enzyme. Mol. Cell. Endocrinol. 105, R11–R17 (1994)CrossRefPubMed A.L. Albiston, V.R. Obeyesekere, R.E. Smith, Z.S. Krozowski, Cloning and tissue distribution of the human 11-beta-hydroxysteroid dehydrogenase type-2 enzyme. Mol. Cell. Endocrinol. 105, R11–R17 (1994)CrossRefPubMed
6.
Zurück zum Zitat K. Sun, K.P. Yang, J.R.G. Challis, Differential expression of 11 beta-hydroxysteroid dehydrogenase types 1 and 2 in human placenta and fetal membranes. J. Clin. Endocrinol. Metab. 82, 300–305 (1997)CrossRefPubMed K. Sun, K.P. Yang, J.R.G. Challis, Differential expression of 11 beta-hydroxysteroid dehydrogenase types 1 and 2 in human placenta and fetal membranes. J. Clin. Endocrinol. Metab. 82, 300–305 (1997)CrossRefPubMed
7.
Zurück zum Zitat J.W. Tomlinson, E.A. Walker, I.J. Bujalska, N. Draper, G.G. Lavery, M.S. Cooper, M. Hewison, P.M. Stewart, 11 Beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 25, 831–866 (2004)CrossRefPubMed J.W. Tomlinson, E.A. Walker, I.J. Bujalska, N. Draper, G.G. Lavery, M.S. Cooper, M. Hewison, P.M. Stewart, 11 Beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 25, 831–866 (2004)CrossRefPubMed
8.
Zurück zum Zitat M. Soldan, G. Nagel, M. Losekam, M. Ernst, E. Maser, Interindividual variability in the expression and NNK carbonyl reductase activity of 11beta-hydroxysteroid dehydrogenase 1 in human lung. Cancer Lett. 145, 49–56 (1999)CrossRefPubMed M. Soldan, G. Nagel, M. Losekam, M. Ernst, E. Maser, Interindividual variability in the expression and NNK carbonyl reductase activity of 11beta-hydroxysteroid dehydrogenase 1 in human lung. Cancer Lett. 145, 49–56 (1999)CrossRefPubMed
9.
Zurück zum Zitat S. Hundertmark, A. Dill, A. Ebert, B. Zimmermann, Y.V. Kotelevtsev, J.J. Mullins, J.R. Seckl, Foetal lung maturation in 11beta-hydroxysteroid dehydrogenase type 1 knockout mice. Horm. Metab. Res. 34, 545–549 (2002)CrossRefPubMed S. Hundertmark, A. Dill, A. Ebert, B. Zimmermann, Y.V. Kotelevtsev, J.J. Mullins, J.R. Seckl, Foetal lung maturation in 11beta-hydroxysteroid dehydrogenase type 1 knockout mice. Horm. Metab. Res. 34, 545–549 (2002)CrossRefPubMed
10.
Zurück zum Zitat M. Wamil, J.R. Seckl, Inhibition of 11B-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov. Today 12, 504–520 (2007)CrossRefPubMed M. Wamil, J.R. Seckl, Inhibition of 11B-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov. Today 12, 504–520 (2007)CrossRefPubMed
11.
Zurück zum Zitat Z. Yang, P. Zhu, C.M. Guo, X.O. Zhu, K. Sun, Expression of 11 beta-hydroxysteroid dehydrogenase type 1 in human fetal lung and regulation of its expression by interleukin-1 beta and cortisol. J. Clin. Endocrinol. Metab. 94, 306–313 (2009)CrossRefPubMed Z. Yang, P. Zhu, C.M. Guo, X.O. Zhu, K. Sun, Expression of 11 beta-hydroxysteroid dehydrogenase type 1 in human fetal lung and regulation of its expression by interleukin-1 beta and cortisol. J. Clin. Endocrinol. Metab. 94, 306–313 (2009)CrossRefPubMed
12.
Zurück zum Zitat Z. Wang, H.H. Tai, Interleukin-1 beta and dexamethasone regulate gene expression of prostaglandin H synthase-2 via the NF-kB pathway in human amnion derived WISH cells. Prostaglandins Leukot. Essent. Fatty Acids 59, 63–69 (1998)CrossRefPubMed Z. Wang, H.H. Tai, Interleukin-1 beta and dexamethasone regulate gene expression of prostaglandin H synthase-2 via the NF-kB pathway in human amnion derived WISH cells. Prostaglandins Leukot. Essent. Fatty Acids 59, 63–69 (1998)CrossRefPubMed
13.
Zurück zum Zitat Z. Yang, C.M. Guol, P. Zhu, W.J. Li, L. Myatt, K. Sun, Role of glucocorticoid receptor and CCAAT/enhancer-binding protein A in the feed-forward induction of 11 beta-hydroxysteroid dehydrogenase type 1 expression by cortisol in human amnion fibroblasts. J. Endocrinol. 195, 241–253 (2007)CrossRefPubMed Z. Yang, C.M. Guol, P. Zhu, W.J. Li, L. Myatt, K. Sun, Role of glucocorticoid receptor and CCAAT/enhancer-binding protein A in the feed-forward induction of 11 beta-hydroxysteroid dehydrogenase type 1 expression by cortisol in human amnion fibroblasts. J. Endocrinol. 195, 241–253 (2007)CrossRefPubMed
14.
Zurück zum Zitat S. Sai, C.L. Esteves, V. Kelly, Z. Michailidou, K. Anderson, A.P. Coll, Y. Nakagawa, T. Ohzeki, J.R. Seckl, K.E. Chapman, Glucocorticoid regulation of the promoter of 11 beta-hydroxysteroid dehydrogenase type 1 is indirect and requires CCAAT/enhancer-binding protein-beta. Mol. Endocrinol. 22, 2049–2060 (2008)CrossRefPubMed S. Sai, C.L. Esteves, V. Kelly, Z. Michailidou, K. Anderson, A.P. Coll, Y. Nakagawa, T. Ohzeki, J.R. Seckl, K.E. Chapman, Glucocorticoid regulation of the promoter of 11 beta-hydroxysteroid dehydrogenase type 1 is indirect and requires CCAAT/enhancer-binding protein-beta. Mol. Endocrinol. 22, 2049–2060 (2008)CrossRefPubMed
15.
Zurück zum Zitat D.N. Payne, I.M. Adcock, Molecular mechanisms of corticosteroid actions. Paediatr. Respir. Rev. 2, 145–150 (2001)CrossRefPubMed D.N. Payne, I.M. Adcock, Molecular mechanisms of corticosteroid actions. Paediatr. Respir. Rev. 2, 145–150 (2001)CrossRefPubMed
16.
Zurück zum Zitat K.E. Chapman, A.E. Coutinho, M. Gray, J.S. Gilmour, J.S. Savill, J.R. Seckl, The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in the inflammatory response. Mol. Cell. Endocrinol. 301(1–2), 123–131 (2008)PubMed K.E. Chapman, A.E. Coutinho, M. Gray, J.S. Gilmour, J.S. Savill, J.R. Seckl, The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in the inflammatory response. Mol. Cell. Endocrinol. 301(1–2), 123–131 (2008)PubMed
17.
Zurück zum Zitat K.E. Willet, B.W. Kramer, S.G. Kallapur, M. Ikegami, J.P. Newnham, T.J. Moss, P.D. Sly, A.H. Jobe, Pre- and postnatal lung development, maturation, and plasticity—Intra-amniotic injection of IL-1 induces inflammation and maturation in fetal sheep lung. Am. J. Physiol.-Lung Cell. Mol. Physiol. 282, L411–L420 (2002)PubMed K.E. Willet, B.W. Kramer, S.G. Kallapur, M. Ikegami, J.P. Newnham, T.J. Moss, P.D. Sly, A.H. Jobe, Pre- and postnatal lung development, maturation, and plasticity—Intra-amniotic injection of IL-1 induces inflammation and maturation in fetal sheep lung. Am. J. Physiol.-Lung Cell. Mol. Physiol. 282, L411–L420 (2002)PubMed
18.
Zurück zum Zitat T. Taniguchi, N. Matsuzaki, T. Kameda, K. Shimoya, T. Jo, F. Saji, O. Tanizawa, The enhanced production of placental interleukin-1 during labor and intrauterine infection. Am. J. Obstet. Gynecol. 165, 131–137 (1991)PubMed T. Taniguchi, N. Matsuzaki, T. Kameda, K. Shimoya, T. Jo, F. Saji, O. Tanizawa, The enhanced production of placental interleukin-1 during labor and intrauterine infection. Am. J. Obstet. Gynecol. 165, 131–137 (1991)PubMed
19.
Zurück zum Zitat L.J.S. Williams, V. Lyons, I. MacLeod, V. Rajan, G.J. Darlington, V. Poli, J.R. Seckl, K.E. Chapman, C/EBP regulates hepatic transcription of 11 beta-hydroxysteroid dehydrogenase type 1—A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways. J. Biol. Chem. 275, 30232–30239 (2000)CrossRefPubMed L.J.S. Williams, V. Lyons, I. MacLeod, V. Rajan, G.J. Darlington, V. Poli, J.R. Seckl, K.E. Chapman, C/EBP regulates hepatic transcription of 11 beta-hydroxysteroid dehydrogenase type 1—A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways. J. Biol. Chem. 275, 30232–30239 (2000)CrossRefPubMed
20.
Zurück zum Zitat C. Nerlov, C/EBPs: recipients of extracellular signals through proteome modulation. Curr. Opin. Cell Biol. 20, 180–185 (2008)CrossRefPubMed C. Nerlov, C/EBPs: recipients of extracellular signals through proteome modulation. Curr. Opin. Cell Biol. 20, 180–185 (2008)CrossRefPubMed
21.
Zurück zum Zitat K. Sun, L. Myatt, Enhancement of glucocorticoid-induced 11beta-hydroxysteroid dehydrogenase type 1 expression by proinflammatory cytokines in cultured human amnion fibroblasts. Endocrinology 144, 5568–5577 (2003)CrossRefPubMed K. Sun, L. Myatt, Enhancement of glucocorticoid-induced 11beta-hydroxysteroid dehydrogenase type 1 expression by proinflammatory cytokines in cultured human amnion fibroblasts. Endocrinology 144, 5568–5577 (2003)CrossRefPubMed
22.
Zurück zum Zitat K. Sun, R.L. Ma, X.L. Cui, B. Campos, R. Webster, D. Brockman, L. Myatt, Glucocorticoids induce cytosolic phospholipase A(2) and prostaglandin H synthase type 2 but not microsomal prostaglandin E synthase (PGES) and cytosolic PGES expression in cultured primary human amnion cells. J. Clin. Endocrinol. Metab. 88, 5564–5571 (2003)CrossRefPubMed K. Sun, R.L. Ma, X.L. Cui, B. Campos, R. Webster, D. Brockman, L. Myatt, Glucocorticoids induce cytosolic phospholipase A(2) and prostaglandin H synthase type 2 but not microsomal prostaglandin E synthase (PGES) and cytosolic PGES expression in cultured primary human amnion cells. J. Clin. Endocrinol. Metab. 88, 5564–5571 (2003)CrossRefPubMed
23.
Zurück zum Zitat M. Oelgeschlager, I. Nuchprayoon, B. Luscher, A.D. Friedman, C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. Mol. Cell. Biol. 16, 4717–4725 (1996)PubMed M. Oelgeschlager, I. Nuchprayoon, B. Luscher, A.D. Friedman, C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. Mol. Cell. Biol. 16, 4717–4725 (1996)PubMed
Metadaten
Titel
Stimulation of 11β-HSD1 expression by IL-1β via a C/EBP binding site in human fetal lung fibroblasts
verfasst von
Zhen Yang
Xiaoou Zhu
Chunming Guo
Kang Sun
Publikationsdatum
01.12.2009
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2009
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-009-9245-4

Weitere Artikel der Ausgabe 3/2009

Endocrine 3/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.